C4 Therapeutics, Inc.
CCCCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Valued at $408.0M, CCCC is a small-cap name in its sector. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Market Cap
$408.0M
Beta
2.91
P/E (TTM)
—
P/E (Fwd)
-3.55
EPS (TTM)
$-1.14
EPS (Fwd)
$-1.04
ROE
-48.4%
ROA
-19.9%
Cash
$235.7M
Total Debt
$58.4M
Free CF
-$53.4M
52W Change
59.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $235.7M in cash comfortably exceeding the $58.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$53.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $31.1M to $35.9M.
C4 Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CCCC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CCCC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.